Technology Listings


Purification of Specific Cell Types from Stem Cells via Fluorescent Probes

Application

Dual-labeled antisense oligonucleotide probes for fluorescent activated cell sorting (FACS) of pluripotent stem cells.

Key Benefits
  • Allows for the purification of a homogeneous cell population compared to currently available techniques which can only produce heterogeneous mixtures.
  • Binds intracellular RNA using standard delivery techniques eliminating the need for known surface markers to be present within the cell population.
  • Specific probes can be generated for different cell types.
Market Summary

The global market for flow cytometry products and reagents was estimated at $2.6 million in 2010. The reagents market comprised the second largest share at $0.8 billion, a number that is expected to reach $1.5 billion by 2015. Flow cytometry sorting techniques have previously used a mitochondrial dye for the purification of mature cardiomyocytes, but these techniques suffer from a lack of specificity and sensitivity. Additional approaches have relied on cell specific proteins and antibodies to enrich a homogeneous population. In this instance purification is often hindered by a lack of known markers.

Technical Summary

The inventors have described cardiomyocyte-specific molecular probes, termed molecular beacons, consisting of an oligonucleotide with a fluorescent emitter at one end and a fluorescent quencher at the other. These dual-labeled molecular beacons are designed to fold back on themselves in the absence of a complementary cellular nucleotide sequence. In the presence of a complementary sequence, the beacon will hybridize with the targeted mRNA sequence and produce a fluorescent signal. The differentiated cells can then be sorted via FACS with high efficiency and specificity using flow cytometry. Because these molecular beacons bind intracellular RNA through traditional delivery systems, the need to first identify a surface protein specifically expressed on the target cell is eliminated. The technology therefore provides a method of purifying cell populations that lack known surface markers.

Developmental Stage

A homogeneous population of cardiomyocytes has been purified from differentiating mouse and human pluripotent stem cells.

Publications: Ban K et al. Circulation. 126:A18585. (2012).

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Utility(parent) United States 14/211,430 9,493,742 3/14/2014 11/15/2016 3/14/2034
Divisional United States 15/273,164 9/22/2016    
Tech ID: 12147
Published: 3/27/2013
Category
Research Tools
Therapeutics

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Young-Sup Yoon
Kiwon Ban
Brian Wile
Gang Bao

Keywords
Cell/Gene Therapy